VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment

Metastatic gastric cancer (mGC) often has a poor prognosis and may benefit from a few targeted therapies. Ramucirumab-based anti-angiogenic therapy targeting the VEGFR2 represents a milestone in the second-line treatment of mGC. Several studies on different cancers are focusing on the major VEGFR2 l...

Descripción completa

Detalles Bibliográficos
Autores principales: Schirizzi, Annalisa, Arshadi, Aram, Tolomeo, Doron, Schirosi, Laura, Valentini, Anna Maria, De Leonardis, Giampiero, Refolo, Maria Grazia, Donghia, Rossella, Storlazzi, Clelia Tiziana, Zito, Alfredo, Ricci, Angela Dalia, Vallarelli, Simona, Ostuni, Carmela, Bencivenga, Maria, De Manzoni, Giovanni, Messa, Caterina, Armentano, Raffaele, Giannelli, Gianluigi, Lotesoriere, Claudio, D’Alessandro, Rosalba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603940/
https://www.ncbi.nlm.nih.gov/pubmed/37893095
http://dx.doi.org/10.3390/biomedicines11102721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603940/
https://www.ncbi.nlm.nih.gov/pubmed/37893095
http://dx.doi.org/10.3390/biomedicines11102721

Ejemplares similares